Millennium Announces Pharmaceutical Industry Leader Joins the Board of Directors
News Feb 10, 2006
Millennium Pharmaceuticals, Inc. has announced the election of Anthony H. Wild, Ph.D., to the Millennium Board of Directors.
Dr. Wild, chairman and chief executive officer of MedPointe Pharmaceuticals, has 30 years of pharmaceutical industry experience including executive positions with Warner- Lambert (now part of Pfizer Inc) and Schering-Plough Corporation.
"We are very pleased to welcome Dr. Wild to the Millennium Board," said Deborah Dunsire, M.D., president and chief executive officer of Millennium.
"We believe that his experience in managing multi-billion dollar commercial operations, major research and development organizations and key business acquisitions will enable him to make significant contributions to the Company's sustained growth and ability to deliver innovative medicines to patients."
Prior to joining MedPointe Pharmaceuticals, Dr. Wild served as executive vice president of Warner-Lambert and president of its pharmaceutical sector. During his tenure, he had worldwide responsibility for the pharmaceutical commercial operations and research and development.
Under his leadership, Warner-Lambert's pharmaceutical sector grew from $2.1 billion in sales with 14,000 employees in 1995 to an estimated $9.5 billion in 2000 with 21,000 employees.
During this period, Dr. Wild oversaw a number of key transactions including the Pfizer global Lipitor® co-marketing partnership.
"This is an exciting time to be a part of the Company's success as Millennium strengthens its commercial presence and accelerates the development of a rich product pipeline," said Dr. Wild.
"I look forward to working together with the Board to enhance the Company's growth and increase shareholder value."
Before joining Warner-Lambert, Dr. Wild spent 22 years with Schering-Plough Corporation in a number of positions across the globe, culminating as president of Schering-Plough's Japanese operations, a $500 million business.
Dr. Wild also served at Sandoz AG as a development chemist, where he worked on optimization and simulation of chemical processes.
Dr. Wild is a member of the Board of Advisors to the Joseph L. Mailman School of Public Health at Columbia University, a Trustee of the Healthcare Institute of New Jersey, past Chairman of the International Section of Pharmaceutical Research and Manufacturers of America and past Governor of the American Chamber of Commerce in Japan.
Dr. Wild's appointment brings the number of directors on the Millennium Board to ten.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE